This study aimed to identify operating conditions and governance mechanisms that would help to facilitate trust in, and willingness to donate to, a hypothetical Australian national genomic repository for health research where commercial use of data is permitted. Semi-structured telephone interviews with members of the Australian public ( = 39) clarified perceived risks and preferred repository conditions. These insights were subsequently tested experimentally in a national sample ( = 1,117).
View Article and Find Full Text PDFObjectives: To reassess the role of primary retroperitoneal lymph node dissection (RPLND) in patients with marker-negative non-seminomatous germ cell tumour (NSGCT) clinical stage (CS) 2a, to explore results in patients with CS 2b and to evaluate surgical methods, recurrence, and adjuvant chemotherapy indications.
Materials And Methods: Data from 17 institutions were collected, comprising 305 men who underwent primary RPLND for CS 2 NSGCT. Regression analyses were conducted to predict histology in the RPLND specimen and disease-free survival (DFS).
Discourse around ownership of genomic sequence data has proliferated over recent years. There are likely to be few people who don't feel a degree of connectedness to their genomic data. The inclusion of individuals' genomic data in genomic datasets is critical to genomic research, and these datasets are most effective if shared widely.
View Article and Find Full Text PDFBorges and colleagues rightly argue that an international treaty is needed to curtail the profit-driven behaviour of the pharmaceutical industry during pandemics. The Pandemic Agreement currently being negotiated by Member States of the World Health Organization (WHO) offers an important opportunity to equip nation states with greater leverage over industry behaviour. In this commentary, we examine the potential of current draft textual proposals for the Pandemic Agreement to redirect pharmaceutical behaviour in future pandemics.
View Article and Find Full Text PDFBackground And Objective: The majority of small testicular masses (STMs) are benign and therefore radical orchidectomy (RO) may represent overtreatment. In appropriately selected patients, surveillance or testis-sparing surgery (TSS) is an alternative option to preserve testicular function. Since there are no clear guidelines, we aimed to develop consensus recommendations on the management of STMs.
View Article and Find Full Text PDF